Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to characterize the safety and tolerability of
GS-4224 and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
of GS-4224 in participants with advanced solid tumors.